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Inhibiting the reproduction of SARS-CoV-2 through
perturbations in human lung cell metabolic network
Hadrien Delattre1, Kalesh Sasidharan1,2 , Orkun S Soyer1,2
Viruses rely on their host for reproduction. Here, we made use of
genomic and structural information to create a biomass function
capturing the amino and nucleic acid requirements of SARS-
CoV-2. Incorporating this biomass function into a stoichiometric
metabolic model of the human lung cell and applying meta-
bolic flux balance analysis, we identified host-based metabolic
perturbations inhibiting SARS-CoV-2 reproduction. Our results
highlight reactions in the central metabolism, as well as amino
acid and nucleotide biosynthesis pathways. By incorporating host
cellular maintenance into the model based on available protein
expression data from human lung cells, we find that only few of
these metabolic perturbations are able to selectively inhibit virus
reproduction. Some of the catalysing enzymes of such reactions
have demonstrated interactions with existing drugs, which can be
used for experimental testing of the presented predictions using
gene knockouts and RNA interference techniques. In summary,
the developed computational approach offers a platform for
rapid, experimentally testable generation of drug predictions
against existing and emerging viruses based on their biomass
requirements.
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Introduction
One of the crucial steps in the virus life cycle is the synthesis of the
virus particles within the host cell. This includes the synthesis of viral
structural proteins and new genomic material. For these processes,
all viruses are fully dependent on their host for the required energy
(Mahmoudabadi et al, 2017) and building blocks (Berzin et al, 1974;
Waldbauer et al, 2019). This dependency is evidenced by experi-
mental findings showing significant metabolic flux alterations in host
cells upon infection (Maynard et al, 2010a; Yu et al, 2011). System-level
metabolic studies have particularly highlighted changes in glucose
uptake and glycolysis (El-Bacha et al, 2004; Munger et al, 2006), which
might be related to an increased demand for biosynthetic precursors
as viral production becomes the dominant process within infected
cells (Berzin et al, 1974).
The observation of virus synthesis dominating the metabolism
and physiology of infected cells suggests that it might be possible
to manipulate cell metabolism to control the viral infection (Ikeda
& Kato, 2007; Maynard et al, 2010). Indeed, several of the existing
antivirals such as ribavirin, remdesivir, and gemcitabine are nu-
cleoside analogs that target metabolic enzymes in the nucleotide
biosynthesis pathways and are thought to function through their
impact on free nucleotide pools in the cell (Leyssen et al, 2008;
Wang et al, 2011). An even more specific metabolic approach to
inhibit virus production was demonstrated in the case of human
cytomegalovirus. For this virus, metabolic analyses highlighted a
shifting of metabolic fluxes within central carbon metabolism and
fatty acid biosynthesis pathways during infection (Munger et al,
2008). It was predicted that these flux changes could be blocked by
perturbation of specific enzymes, which were then targeted with
available inhibitors and resulted in reduced virus production
(Munger et al, 2008). Systematic analysis of gene knockout effects
on infection of bacteria with phage also identified many metabolic
genes associated with central carbon metabolism and substrate
transport (Maynard et al, 2010b), leading to the proposition of using
host metabolic engineering to modulate viral production (Maynard
et al, 2010a). Such metabolic control has been explored in virus-
based bioproduction using insect cells, where alterations in the
culture media allowed alteration of metabolic fluxes and pro-
duction levels (Carinhas et al, 2010).
These experimental findings show that viral biomass synthesis
causes significant metabolic flux changes in host cells and that
metabolic perturbations can directly alter virus reproduction. Thus,
system-level metabolic models could be used to predict what types
of metabolic alterations can cause what kinds of impact on virus
reproduction. Although modelling of virus reproduction in host
cells has mostly taken a kinetic approach, focusing on translation
and transcription processes (Endy et al, 1997; You et al, 2002; Yin &
Redovich, 2018), it has been possible to combine such kinetic
models with genome-scale metabolic models to account for both
host and virus biomass (Jain & Srivastava, 2009). This allowed
predicting the effects of metabolites available in the culture media
on the dynamics of the infection process (Birch et al, 2012). In a
human cell context, genome-scale metabolic models were used to
analyse the metabolic impact of infection of macrophages with
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bacteria or viruses (Bordbar et al, 2010; Aller et al, 2018). One of
these studies incorporated viral production into the macrophage
metabolic model and predicted specific reaction perturbations that
can cause a reduction in viral reproduction (Aller et al, 2018). These
predictions correctly identified enzyme targets of the aforemen-
tioned antiviral drugs in nucleotide pathways and highlighted new
target enzymes (Aller et al, 2018). Such findings from the virus-host
metabolic modelling aligns with the observations that genome-
scale metabolic models can provide a comprehensive stoichio-
metric catalogue of possible biochemical conversions in a cell
(Thiele et al, 2013; Swainston et al, 2016) and can generate useful
qualitative predictions on the impact of environmental or genetic
alterations on the cellular metabolic flux distributions (Edwards &
Palsson, 2000; Segrè et al, 2002; Papp et al, 2004).
Motivated by the qualitative predictive power of stoichiometric
metabolic models and flux analysis, we apply it here to simulate the
production of SARS-CoV-2 virus particles as part of the host
metabolism and predict metabolic inhibitions against this virus.
Given the emerging literature on SARS-CoV-2 infection primarily
targeting lung and intestinal cells, we focus here on human lung
cells as the host system. We adapt the available human genome-
scale metabolic model with a biomass maintenance function based
on human lung tissue–derived expression data, and include in this
model also a viral biomass reaction, estimated using structural
information available from SARS-CoV-2 and related viruses. By
optimising flux distributions in this “infected lung cell model” for
viral biomass reaction, we were able to predict reactions whose
suppression or constraint can theoretically inhibit viral repro-
duction. We explored the possible impact of these predicted in-
hibitions on the host metabolism itself, as well as the experimental
feasibility of implementing the predicted metabolic perturbations
using available drug and inhibitor information on metabolic en-
zymes. Our results indicate that individual and double perturbation
of several metabolic reactions from central metabolic pathways
can inhibit SARS-CoV-2 reproduction in general and some of these
can do so selectively without affecting normal metabolic functions
of the host. We highlight these reactions as experimentally testable
drug targets for inhibiting SARS-CoV-2 reproduction in human lung
cells and provide details of the implemented computational ap-
proach for further development.
Results
To simulate the production of SARS-CoV-2 virus particles in a
human cell, we used an existing, community-developed human
genome scale model known as RECON2.2 (Thiele et al, 2013;
Swainston et al, 2016) (see the Materials and Methods section). This
model represents the most comprehensive catalogue of metabolic
reactions found in human cells, with many of its reactions asso-
ciated with known genes (Swainston et al, 2016). Within this model,
we implement a pseudo reaction representing the production of
SARS-CoV-2 viral particles from biosynthetic precursors (see Fig 1A
and the Materials and Methods section). The construction of this
pseudo reaction is based on available structural information on the
virus including its use of proteins for viral packaging (Neuman et al,
2006; 2011; 2008; Bárcena et al, 2009, Mahmoudabadi et al, 2017, Bar-
On et al, 2020) and its genome sequence. As such, this pseudo
biomass reaction accounts for the stoichiometry of nucleic and
amino acids required to make a complete virus and associated
energetic costs. This analysis highlights that leucine and alanine
are the most used amino acids in SARS-CoV-2 proteins, and
adenosine- and uridine-triphosphate are the more common
nucleotides in its RNA (Fig 1B).
Metabolic fluxes supporting SARS-CoV-2 production in a human
cell are primarily in central carbon metabolism
By incorporating the SARS-CoV-2 viral biomass function into the
human metabolic model and assuming a minimal media com-
position (see the Materials and Methods section), we predict a
metabolic flux distribution for optimal virus production in a
human cell (Fig 1C). We then evaluated the flux variability allowed
in each reaction of the model, while maintaining an optimal viral
production level (Table S1). These analyses have shown that
reactions which must carry flux for optimal viral biomass pro-
duction include glycolysis, oxidative phosphorylation, fatty acid
oxidation, and specific amino and nucleic acid biosynthesis
pathways (Fig 1C and Table S1). As the optimal flux distributions
are related also to the flux limits imposed on uptake reaction
fluxes, we also repeated the flux variability analysis with minimal
media but using an increased uptake limit, and with a rich media
that allows all uptake reactions of the model to be active. In-
creasing the uptake limits did not alter the general conclusions
about key active pathways sustaining optimal virus production
but resulted in higher uptake fluxes, which cause additional
pathways relating to overflow metabolism to be active (Table S1).
Simulating a rich media resulted in a much lower number of flux-
carrying reactions, as the cell can obtain several key compounds
such as uridine triphosphate from the media under this scenario
(Table S1). Because this rich media allows all transport reactions
in the RECON2.2. model to carry flux, providing the cell access to
most building blocks, we believe it is physiologically rarely, if it
all, achieved (e.g., limitation of amino acids). We therefore focus
the remaining analysis on the results from simulations using the
minimal media.
Inhibiting specific metabolic enzymes and enzyme combinations
inhibit SARS-CoV-2 production in human cells
To identify reaction perturbations which, when inhibited, can halt
or reduce virus production, we systematically simulated a knockout
of each flux-carrying reaction. Excluding reactions involved in
uptake from media, this analysis highlighted 35 reaction knockouts
that can stop virus production and an additional eight reactions
that can reduce it below 80% of the original (Fig 1C). The former
group of reactions tended to be involved in nucleotide and amino
acid biosynthesis pathways, whereas the latter group included
reactions primarily in glycolysis and oxidative phosphorylation
(Tables 1 and S2). Key ones among these reactions are further
discussed below.
Considering that it is possible for the effects of single pertur-
bations to be circumvented by re-directing of fluxes, we also
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explored combined perturbations. We created all possible pairs of
flux-carrying reactions according to the flux variability analysis
(more than 5,000 pairs) and simulated the effect of setting their
reaction fluxes to zero. This has identified more than 400 reaction
pairs, co-inhibition of which results in the reduction of virus optima
to 80% or less of the original (Tables 1 and S2). Most of these re-
action pairs involved one of the 10 single perturbations that were
found to reduce virus production to less than 80% on their own, but
pairing them with additional reaction increased their impact. For
example, inhibition of GAPD and cytochrome c oxidase (CYOR)
individually caused reduction to 62% and 60% of original virus
production respectively, but combined inhibition of these reactions
results in 25% of original production (Table S2). Some of these cases
of increased effect arise due to co-inhibition of reactions more
effectively blocking fluxes into virus biomass precursors. For ex-
ample, combined blocking of GAPD and CYOR, reactions involved in
respiration and glycolysis, respectively, results in reduced fluxes
into pyruvate and alpha-ketoglutarate (akg), a key intermediary of
the tricarboxylic acid (TCA) cycle. Akg is further linked into valine
production through a valine:3-methyl-2-oxobutanoate shuttle
across the mitochondrial membrane (Fig 2). In the optimal flux
distribution for SARS-CoV-2 production, this “valine shuttle” has
a high flux and contributes to the production of both valine and
multiple other amino acids via mitochondrial glutamate (Fig 2B).
Perturbations to both CYOR and GAPD lead to a new flux dis-
tribution where the glutamate production in the mitochondrial
matrix is sustained through a different metabolic route (Fig 2A).
The “valine shuttle” that was active in the optimal solution is
now non-functional and is instead replaced by a leucine: 4-
methyl-2-oxopentanoate shuttle carrying a lesser flux. This in
turn decreases the production of the amino acids from gluta-
mate, and thus causing a significant decrease in virus biomass
production flux (Fig 2).
In the case of simulating the minimal media with higher uptake
fluxes, we have also identified pairs of completely new enzyme
inhibitions, which were not causing any effect on their own (Table
S2). Some of these pairs exert their effects by blocking multiple
pathways from a given compound and thereby causing disruption
Figure 1. Model schematic, virus biomass analysis, and model fluxes. (A) Schematic representation of the integrated host–virus metabolic modelling approach used in
this article. The biomass composition of SARS-CoV-2 is estimated as described in the Materials and Methods section and then embedded in the metabolic network
model of the host cell. This model is then used to predict the metabolic fluxes supporting virus production and effects of perturbations as described in the main text. (B)
Composition of virus biomass in mmol per gram of virus biomass dry weight. The two panels show amino acids and nucleotides as labelled. (C) Graph representation of
part of the human cellular metabolic network, focusing on those reactions that are active in virus production under minimal media conditions with uptake fluxes set to
−10 mmol gDW−1 h−1 (see main text and the Materials and Methods section). The cell is shown as a circle with a grey background, with the mitochondrial matrix shown in
white background. Nodes are metabolites and edges are reactions. Edges between two nodes are drawn when at least one reaction connecting those two metabolites
carries flux in the optimal flux distribution. The graph shown here is obtained from the full metabolic network by selecting those edges corresponding to the shortest
path between metabolites present in the medium and the precursor metabolites to amino acids that contribute to the virus biomass. The paths are found by using the
Dijkstra algorithm (Dijkstra, 1959) and weighting the edges by the inverse of their flux value. Nodes are coloured by their cellular location; cytosol (black), mitochondrial
matrix (grey), and external medium (green). Node labels are coloured also according to primarily location, with amino acids and media components labelled in green
and yellow, respectively. Key reactions discussed in the text and summary results are labelled on their corresponding edges.
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in steady state balances in the model. For example, co-inhibition of
citrate synthase (CSm) and several other enzymes such as histidase
(HISD) totally prevents flux in SARS-CoV-2 biosynthesis reaction by
making impossible the mass balance of protons in the cytosol (see
Fig S1).
Metabolic requirements of viral production are different to those
arising from host cellular maintenance
In the above discussed analyses, we considered host metabolism
as optimised for viral production and evaluated impact of per-
turbations only on this process. Such metabolic perturbations
should also be evaluated for their impact on the normal metabolic
functions of uninfected host cells. In previous studies, normal state
of metabolism in human cell lines are either represented through a
pseudo reaction for cellular maintenance (Bordbar et al, 2010;
Thiele et al, 2013) or through consideration of specific metabolic
functions such as ATP or lipid production (Mardinoglu et al, 2014). In
the former case, cell maintenance is captured by a generic account
of cellular constituents such as lipids, carbohydrates and DNA and
a more specific accounting of amino acid usage in protein ex-
pression (Bordbar et al, 2010; Thiele et al, 2013). In RECON2.2, the
protein-based component of the maintenance function is calcu-
lated from a large collection of human genes’ open reading frames
(Thiele et al, 2013).
Here, we expanded from this approach to focus on human lung
cells, which are shown to be the primary target of SARS-CoV-2 in-
fections along with intestinal cells (Cagno, 2020). To create a lung
cell–specific biomass maintenance function, we calculated the
biomass protein components using available expression data
Table 1. Selection of reaction perturbations predicted to reduce SARS-CoV-19 biomass production in a human cell with equal or less impact on human
lung cell-based metabolic maintenance.
Reaction 1 Reaction 2 Virus optima Host optima Perturbation
ATPS4m — 75 77 Knockout
ENO — 65 66 Knockout
PGM — 66 67 Knockout
CYOR — 61 69 Knockout
CYOR GAPD 25 30 Knockout
CYOR PUNP3 60 69 Knockout
CYOR ASPTA 60 68 Knockout
PGK FTCD 58 59 Knockout
ASPCTr — 76 100 Enforcement
CBPS — 76 100 Enforcement
DHORD9 — 76 100 Enforcement
DHORTS — 76 100 Enforcement
OMPDC — 76 100 Enforcement
ORPT — 76 100 Enforcement
ASNS1 — 78 100 Enforcement
GLNS — 84 100 Enforcement
THRD_L — 84 100 Enforcement
LEULEULAPc — 90 100 Enforcement
LEULEUPEPT1tc — 90 100 Enforcement
ASPCTr DHFR 73 100 Enforcement
CBPS DHFR 73 100 Enforcement
DHORD9 DHFR 73 100 Enforcement
DHORTS DHFR 73 100 Enforcement
OMPDC DHFR 73 100 Enforcement
ORPT DHFR 73 100 Enforcement
Individual or pairs of reaction perturbations are shown, alongside their predicted effects on SARS-CoV-19 and host as percent of optima without any
perturbations. For full results, see Tables S2 and S5. Reactions are identified with the short notation used in the RECON2.2 model and their gene and subsystem
associations are given in Table S1. Short notations used are: ATPS4m, ATP synthase; ENO, enolase; PGM, phosphoglycerate mutase; CYOR, ubiquinol-6
cytochrome c reductase; GAPD, glyceraldehyde-3-phosphate dehydrogenase; PUNP3, purine-nucleoside phosphorylase (Guanosine); ASPTA, aspartate
transaminase; PGK, phosphoglycerate kinase; ASPCTr, carbamoyltransferase; CBPS, carbamoyl-phosphate synthase; DHORD9, dihydroorotic acid
dehydrogenase; DHRTS, dihydroorotase; OMPDC, orotidine-5-phosophate decarboxylase; ORPT, orotate phosphoribosyltransferase; ASNS1, asparagine
synthase; GLNS, glutamine synthase; THRD, threonine deaminase.
Metabolic inhibition of SARS-CoV-2 Delattre et al. https://doi.org/10.26508/lsa.202000869 vol 4 | no 1 | e202000869 4 of 12
Figure 2. Effect of the double knockout of GAPD and cytochrome c oxidase (CYOR) on the optimal flux distribution for virus production under minimal media
conditions with uptake fluxes set to 210 mmol gDW21 h21.
(A) Distribution of the producing (“in”) and consuming (“out”) fluxes for valine in the cytosol and glutamate in the mitochondrial matrix. For each metabolite, the in and
out fluxes have been computed for the unmodified model (left) and for the double knockout of GAPD and CYOR (right). (B) Cartoon representation of the reaction network
involving valine and othermetabolites, with reaction fluxes from normal and perturbation conditions colour-mapped onto reaction arrows. The upper panel represents
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available from the Human Protein Atlas project for lung tissue (Uhlén
et al, 2015) (see the Materials and Methods section). Comparing the
resulting human lung cell maintenance function to the SARS-CoV-2
biomass, in terms of the building block stoichiometries, revealed dif-
ferences in relative amino and nucleic acid usage (Fig 3 and Table S3).
Compared with the host, there was particularly higher relative usage of
phenylalanine, isoleucine, asparagine, threonine, tryptophan, and ty-
rosine in the virus and particularly lower relative usage of glutamate,
histidine,methionine, andproline (Fig 3). Accordingly, theoptimisationof
the model using the host metabolic maintenance results in a different
metabolic flux distribution compared with viral production (Table S4).
The differences, however, were rather limited from the perspective of
fluxes supporting SARS-CoV-2 production; out of all reactions that must
carry a flux to sustain a virus optimal state, almost all were also required
to carry flux to sustain a host optimal state (Table S4).
Flux control can ensure selective reduction in viral production
Given the above finding that the same reactions carrying flux for
SARS-CoV-2 production also carry flux for host metabolic main-
tenance, we re-analysed the effects of enzyme perturbations on
both virus and the host. We found that many of the previously
identified single perturbations limiting virus production also lim-
ited significantly the host metabolic maintenance, with only one
single perturbation—that involving CYOR—showing more than 5%
difference in its impact on virus versus the host (Table S5). The
same finding prevailed for double perturbations. The only pairs that
displayed 5% ormore difference in their effects on virus versus host
are those involving CYOR paired with other enzymes (Table S5).
The limited differential impact of full inhibition of enzymesmade
us postulate that more refined perturbations could provide a better
strategy to just impact SARS-CoV-2 production without affecting the
host. In particular, given the differences in optimal metabolic fluxes
between virus production and host maintenance states, we argued
that there might be flux values for some reaction that are com-
patible with only one of these states. To explore this possibility, we
systematically analysed the flux variability of each reaction given
either the optimisation of host maintenance or virus production.
This has allowed us to see if any of the reactions would have flux
regimes that are only compatible with the optimal host mainte-
nance but not with optimal virus production and then “enforce”
such flux regimes on the model. This approach allowed us to
identify few single and double reaction perturbations that are fully
selective on their effect and solely reduce virus production without
causing any impact on the host (see Table S6). They involved a small
number ofmetabolic reactions, namely, aspartate carbamoyltransferase
(ASPCTr), carbamoyl-phosphate synthase (CBPS), dihydroorotic acid
dehydrogenase (DHORD9), dihydroorotase (DHRTS), orotidine-5-
phosphate decarboxylase (OMPDC), orotate phosphoribosyl-
transferase (ORPT), asparagine synthase (ASNS1), glutamine synthase
(GLNS), and threonine deaminase (THRD) and caused up to 27%
reduction in SARS-CoV-2 production (Table S6).
The flux enforcement approach creates further constraints on
how the metabolic fluxes in the system can be balanced at steady
state. For example, in the optimal flux distribution for SARS-CoV-2
production in the unmodified model, threonine is obtained from
themedium through a threonine:leucine shuttle, with both of these
amino acids being in relatively similar demand between host and
virus requirements. In the case of THRD fluxes enforced to specific
Figure 3. Compositional comparison of SARS-CoV-2 biomass and host maintenance based on human lung cell protein expression.
The values on the y-axis of both panels are the base 2 logarithms of the ratio of the proportion of each metabolite (amino acid or nucleotide) in the virus biomass
divided by its proportion in the host maintenance function. The proportion of each metabolite is its stoichiometric coefficient in the corresponding reaction (virus
biomass or host maintenance) in mmol gDW−1, divided by the sum of all stoichiometric coefficients in that reaction.
the flux distribution in the normal condition, whereas the lower panel represents flux distribution under perturbation, that is, when both GAPD and CYOR are knocked
out. The light grey rectangle represents the mitochondrial compartment. Metabolite notations used are: 3-methyl-2-oxobutanoate (3mob), 4-methyl-2-oxopentanoate
(4mop), alpha-ketoglutarate (akg), 4-oxobutanoate (sucsal), and gamma-aminobutyric acid (4abut).
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Figure 4. Effect of the flux enforcement of threonine deaminase (THRD) on the optimal flux distribution for SARS-CoV-2 production.
The enforced flux boundaries were (8.94; 9.14) mmol gDW−1 h−1 for THRD. (A) Distribution of the producing (“in”) and consuming (“out”) fluxes for arginine and isoleucine
in the cytosol and succinate in the mitochondrial matrix. For each metabolite, the in and out fluxes have been computed in two different conditions; from left to right;
unmodified model and flux enforcement of THRD only. (B) Cartoon representation of the reaction network involving threonine and other amino acids, with reaction fluxes
from normal and perturbation conditions shown above and below the dashed line, respectively. Flux values are colour-mapped onto reaction arrows. Metabolite
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ranges, threonine is instead obtained through a threonine:iso-
leucine shuttle and is now further intertwined with the arginine:
isoleucine shuttle, thereby creating a trade-off among these amino
acids (Fig 4). Crucially, arginine is the highest and isoleucine the
third highest differentially demanded amino acid when comparing
virus with host requirements (Fig 3). This is why the described trade-
off situation among these amino acids and threonine, caused by
the flux enforcement, differentially impacts the SARS-CoV-2 bio-
mass production more than it effects host maintenance.
Motivated by this finding, we also simulated the effect of the
decreased availability of specific metabolites in the culture me-
dium on the host and virus biomass fluxes. The maximum import
rate of the different molecules of the minimal medium we defined
was set to values ranging between 0.1 and 10 mmol/gDW/h (where
DW stands for grams of dry weight) and host and viral biomass
optima compared (Table S7). As the maximum import rate of any
molecule of the minimal medium decreases, so does the value
of the optimal biomass flux of both host and virus. In some
cases, namely, for threonine, glycylphenylalanine, and 3-methyl-2-
oxovalerate, this decrease occurs more readily for the virus’ optimal
biomass flux than for the host. This could be interpreted that a
situation of low availability of the aforementioned molecules in the
medium is more detrimental to the virus replication than to the
host’s maintenance.
Current metabolic drugs exist that could target predicted
reactions to inhibit production of SARS-CoV-2
The metabolic approach used here allowed prediction of several
reactions and reaction combinations that could limit SARS-CoV-2
production in human cells in general and differentially in human
lung cells. The significant ones of these are re-summarised in Table
1 as those reactions, the perturbation of which, can reduce virus
production below 80% of the original (see Supplementary files for
full results). For these reactions, we evaluated their associated
enzymes in the light of existing, approved drugs using the available
small molecule inhibitor and drug database DrugBank (Wishart
et al, 2018). We found several existing drugs that could inhibit some
of the predicted reactions including those targeting enolase (ENO),
phosphoglycerate mutase (PGM), and SUCD1m (Table 2). These
drugs could be used as a starting point to experimentally test the
predictions made here, using in vitro assays. In addition to these
identified small molecule inhibitors, we note that it might also be
possible to achieve development of de novo metabolic gene
knockout approaches using recent CRISPR and RNA-silencing
approaches.
Discussion
Here, we have created a stoichiometric biomass function for the
COVID-19–causing SARS-CoV-2 virus and incorporated this into a
human lung cell genome scale metabolic model. The viral biomass
function highlights the key building blocks required to synthesize a
SARS-CoV-2 virus and its simulation within the human metabolic
model enables predicting optimal flux distributions in the host for
sustaining either SARS-CoV-2 reproduction or host maintenance.
We used this capability to identify reaction perturbations that can
inhibit SARS-CoV-2 reproduction in general or selectively, without
inhibiting the host metabolic maintenance. The identified reactions
primarily fall onto glycolysis and oxidative phosphorylation path-
ways and their connections to amino acid biosynthesis pathways.
The latter finding is in line with the additional observation wemade
here that the relative stoichiometries of specific amino acids differ
in SARS-CoV-2 biomass versus host cell maintenance estimated
using human lung cell protein expression data. Together, these
results highlight the possibility of targeting host metabolism for
inhibition of SARS-CoV-2 reproduction in human cells in general
and in human lung cells specifically.
The predictions presented here are based crucially on the
structure of the metabolic model as well as the two key assumptions
of the flux balance analysis (FBA), namely, the assumptions of
metabolic steady state and the optimality of metabolic fluxes
towards a specific metabolic function. In the case of the key
assumptions of FBA (Schuster et al, 2008; Raman & Chandra,
2009), these are expected not to affect qualitative predictions
Table 2. Existing drugs that are approved or investigated for clinical use and that can target some of the enzymes predicted in this study as causing
metabolism-based reduction of SARS-CoV-2 biomass production.
Reaction Enzyme Approved drug or inhibitor Current use DrugBank ID References (PubMed ID)
ATPS4m ATP synthase subunit a Estradiol Hormone therapy DB00783 12587531; 23274738
ATPS4m ATP synthase subunit c Bedaquiline Antimicrobial DB08903 17496888
ENO Enolase Sodium fluoride Antimicrobial DB09325 9227132; 16411755
PGM/PGK Phosphoglycerate mutase Artenimol Antimicrobial DB1163 26340163
PGM/PGK Phosphoglycerate mutase Copper Diet supplement DB09130 15359738
FTCD Formimidoyltransferase cyclodeaminase Pyridoxal phosphate Diet supplement DB00114 17016423
SUCD1m Succinate dehydrogenase Ubidecarenone Diet supplement DB09270 16551570
Information is collated from DrugBank database (Wishart et al, 2018). The reaction abbreviations are as in Table 1.
notations used are: threonine (Thr), 2-oxobutanoate (2obut), leucine (Leu), isoleucine (Ile), arginine (Arg), glutamate (Glu), 3-methyl-2-oxovalarate (3mop), and alpha-
ketoglutarate (akg).
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on which metabolic reactions might be required to carry flux for
a given metabolic process or how specific perturbations might
impact such processes. For example, FBA-based approaches
have been successful in predicting and explaining experimental
observations on gene deletion and environmental perturba-
tions in both microbial (Ibarra et al, 2002) and eukaryotic
systems (Papp et al, 2004). Ultimately, the “infected host cell
models” should be developed in conjunction with experiments
on infected cells, as well as detailed information on virus
stoichiometry, which has been performed in the case of other
viruses (Munger et al, 2006).
There is unfortunately not much available literature yet on SARS-
CoV-2–infected cells and their metabolism, to allow us detailed
comparison betweenmodel predictions and experiments. This said,
we have identified a pre-print under review, which used a colon
epithelial carcinoma cell line as a model system to study impact of
SARS-CoV-2 infection on cell physiology (Bojkova et al, 2020). In
brief, this study has found that cholesterol synthesis is down-
regulated, whereas synthesis of RNA-modifier proteins as well as
carbon metabolism is up-regulated in infected cells. Furthermore,
this study experimentally shown that inhibiting glycolysis as a
whole with a drug decreases the replication rate of the SARS-CoV-2
in this model system. These findings, and additional findings from
other cell lines and virus infections (El-Bacha et al, 2004; Munger
et al, 2006) show that our overall findings are experimentally
supported and that targets such as ENO, GAPD, PGM, and PGK, which
involve in glycolysis and the entrance to the TCA cycle can be
indeed promising drug targets for inhibiting SARS-CoV-2 replication
in cells.
In terms of model result dependence on the model structure,
we used the RECON2.2 model (Thiele et al, 2013; Swainston et al,
2016). This curated human genome scale model contains confi-
dence levels for most included reactions and associated gene
information, which can be improved by future studies updating
the model structure (making use, e.g., of the more recent RECON3D
[Brunk et al, 2018]). This is an area of active development for
genome-scale models (Chindelevitch et al, 2015) and any future
developments of model structure are bound to improve subse-
quent downstream analyses like this one. By adapting this
model’s biomass function to human lung cells—using available
data from the Human Atlas Proteome project—we aimed to create
a model that mimics the natural target cells of the SARS-CoV-2,
namely lung and intestinal cells (Uhlén et al, 2015).
In our view, this approach should bemore informative than using
existing cell-specific models that are not experimentally shown the
be SARS-CoV-2 targets, such as the macrophage model, which has
been used recently in a pre-print to study SARS-CoV-2 infection
(Renz et al, 2020). Besides using the human alveolar macrophage
for the host model, that study has also used parsimonious hy-
potheses to build the virus biomass stoichiometry, assuming an
arbitrary and single number for the copy number of each viral
structural protein. Instead, and as explained above, we use an
estimation based on experimental studies on coronaviruses, in-
cluding SARS-CoV-2. As a result, some differences can be observed
when comparing the two model’s virus stoichiometry, mainly re-
garding the number of required ATP hydrolyses. These differences
in host model and virus biomass construction are expected to lead
to different results between the two studies, yet, interestingly, both
studies shared also some targets such as guanylate kinase (GK1).
The virus life cycle consists of environmental circulation, in-
fection, and subsequent host cell attachment and entry, repro-
duction within the host cell, and exit for a new round of infection.
The presented approach focuses solely on the reproduction within
the host cell and the metabolic aspects of that. Although this is a
limited focus, reproduction in the host cell is a crucial and essential
aspect of the virus life cycle. The importance of this stage is
highlighted in several studies, which demonstrate that viruses tend
to re-program host metabolism for increased viral production (El-
Bacha et al, 2004; Munger et al, 2006, 2008; Yu et al, 2011) or encode
enzymes that can participate in host metabolic functions (Maynard
et al, 2010a). These findings show that metabolic basis of host-virus
interaction is crucial for the success of viruses and suggests that
such interaction could be under significant evolutionary selection.
Emergent viruses, such as SARS-CoV-2, are argued to not be well-
adapted to their new host and undergo rapid evolution dictated by
host-determined factors (Simmonds et al, 2019). It has been
highlighted, for example, that there is a codon usage bias in virus
genomes that possibly evolve in time to align with their host (Wong
et al, 2010). The presented approach suggests that there might be a
similar adaptation of viruses to their host metabolism.
We argue that differences in metabolic requirements of a virus
versus its host could be a “physiological mismatch” that contributes
to this evolutionary dynamic. Before metabolic adaptations hap-
pen, however, inhibition of the hostmetabolismmight be a possible
strategy to selectively inhibit reproduction of emergent viruses in
new hosts. Specific host-based metabolic perturbations have al-
ready been shown experimentally to be effective against viruses
(Munger et al, 2008; Carinhas et al, 2010), whereas general per-
turbation of end points of nucleotide biosynthesis through nu-
cleoside analogs underpins the mode of action of several existing
antiviral drugs. The predictions listed here present possible new
antiviral targets that are primarily within central carbon meta-
bolism, and in particular in glycolysis and oxidative phosphory-
lation. There are already several drugs that are shown to interact
with the predicted enzymes in this study, opening up the possibility
of experimentally testing the presented predictions using in vitro
assays and cell cultures. In addition, latest techniques for con-
trolling enzyme levels from genetic knockout to RNA-based in-
terference strategies or optogenetic approaches (Sahin et al, 2007;
Baaske et al, 2018) can be adapted to implement presented pre-
dictions involving flux enforcements.
In the development of host-based metabolic strategies to inhibit
viruses, metabolic modelling, as presented here, can play a useful
role. In particular, our approach can be applied relatively rapidly to
any host–virus pair both for existing and emerging viruses, and
allow generating experimentally testable hypotheses for virus in-
hibition. This approach can be applied as long as structural and
genomic information can be converted into an estimation of bio-
mass composition for the virus and a suitably detailed metabolic
model for the host can be constructed. The former process can be
enhanced by further databases of viral structural and genomic
information, whereas the latter process would benefit from
extending human-focussed efforts such as the human metabolic
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atlas database (Robinson et al, 2020) to cover also cell lines of
common animal hosts.
Materials and Methods
Human genome-scale metabolic model and its adaptation to
human lung cells
To identify specific host metabolic reactions that can alter viral pro-
duction, we make use of a generic human cell genome-scale metabolic
model that has been previously developed (Thiele et al, 2013) and that
has been subsequently curated and improved by the systems biology
community (Swainston et al, 2016). This model, referred as RECON2.2
contains more than 8,000 reactions, many of which have associated
gene and protein information (Swainston et al, 2016). This model also
contains a pseudo reaction representing genericmaintenance costs of a
human cell, including ATP and precursor stoichiometries for proteins,
DNA, RNA, lipids, and carbohydrates. This pseudo biomassmaintenance
reaction is primarily derived using information from human leukaemia
cell lines (Thiele et al, 2013). This generic human cell model represents a
consensus human metabolic capacity, and as such, its use in this study
allows identification of widest range of possible metabolic reactions
which can then be further scrutinized and sifted in a cell-specific
context.
As discussed in the main text, when identifying metabolic perturba-
tions that can selectively affect viral production without much affecting
the host, the specifics of theusedhostmaintenance representationmust
be cell specific. To align this representation to a lung cell, we have made
use of the gene expression data available from the Human Protein Atlas
project (Robinson et al, 2020). In particular, we have used the gene
expression profile from mechanically homogenized whole tissue lung
sample available from this project and available protein se-
quences from ENSEMBL database (Yates et al, 2020) to create a lung
cell–specific stoichiometry for amino acids required for protein syn-
thesis. The proportion of each amino acid in the composition of the new
maintenance function was determined by converting the protein coding
RNA’s codons to amino acids, counting their frequency and weighing
these with the normalised expression coefficient provided by the Hu-
man Protein Atlas project. The energy cost associated with amino acid
polymerisation is also accounted for based on the length of the protein
sequences and assuming 4.3 molecules of ATP hydrolysed to ADP per
amino acid polymerisation (Quek et al, 2014). The stoichiometric coef-
ficient for each amino acid in the new maintenance function is then
scaled so as to represent the same weight as the original protein
synthesis reaction in the RECON2.2 model (not accounting for ATP, ADP,
Pi nor H2O in the scaling) (see the Data Availability section). The
remaining elements of themaintenance functionwere retainedas in the
RECON2.2 model. The final, lung cell–specific maintenance function is
provided in Table S3.
Creation of SARS-CoV-2 virus biomass function
The biomass function for the SARS-CoV-2 is created as in a previous
study (Aller et al, 2018) and by accounting for the composition and
stoichiometry of proteins and genomic material in the virus.
Composition of protein and virus genome sequences are obtained
from the National Centre for Biotechnology Information (NCBI)
nucleotide database (accession number NC_045512). For one virus
particle, the number of copies of genome (Cg) is assumed to be 1,
whereas the number of copies of structural proteins is assumed to
be 1,540 for membrane glycoproteins (M), 270 for surface glyco-
proteins (S), 490 for nucleocapsid phosphoproteins (N), and 5 for
each of the other structural proteins of SARS-CoV-2. These protein
copy numbers and stoichiometries are estimated from electron
microscopy andmass spectrometry studies on other coronaviruses,
including SARS-CoV (Neuman et al, 2006; 2011; 2008, Bárcena et al,
2009, Mahmoudabadi et al, 2017), and is further checked against a
recent estimate specific to SARS-CoV-2 (Bar-On et al, 2020). The
number of moles of each nucleotide required per virus particle is
obtained from the sequence of the SARS-CoV-2 genome, accounting
for the need to also produce an antisense strand. Similarly, the
number of moles of each amino acid per virus particle is obtained
by multiplying the amount of amino acid found in each protein
sequence by the copy number assumed for that protein. Energetic
costs in form of ATP stoichiometry is computed assuming 4.3 and 1.4
molecules of ATP is hydrolysed to ADP per amino acid and nu-
cleotide polymerisation respectively (Quek et al, 2014). Once the
total number of moles of each nucleotide, amino acid, and ATP
required per virus particle is estimated, the total molar weight per
virus particle is determined and the SARS-CoV-2 biomass biosyn-
thesis reaction stoichiometry is expressed in mmol per gram of
virus. The final biomass function is provided in Table S3, whereas
the computer code used to calculate it is made available (see the
Data Availability section). The modified version of the RECON2.2
containing the lung host biomass function described in the sub-
section above as well as the virus biomass function described in
this section is available in SBML 3 version 1 format (Hucka et al,
2018) as Supplemental Data 1 and accessible online at BioModels
database (Malik-Sheriff et al, 2020) under id MODEL2010280002.
Simulation of the metabolic model
The integrated genome-scale metabolic model was simulated
using the FBA approach (Bordbar et al, 2010). FBA assumes steady
state of metabolic fluxes and implements linear optimisation to
find one particular flux distribution across all reactions that can
satisfy this assumption and that is optimal under given flux con-
straints and a certain optimality criterion. Here, we used the
standard mathematical implementation of FBA as described before
(Bordbar et al, 2014) and usedmaximisation of flux through the host
maintenance or viral biomass pseudo reactions. All reaction flux
constraints are kept as in the original RECON2.2 model except for
extracellular transport reactions. The extracellular transport re-
actions are normally set to carry negative flux to represent uptake
of metabolites from the media. In the RECON2.2 model all extra-
cellular transport reactions’ minimum flux values are set to −1,000
mmol gDW−1 h−1 (where DW stands for grams of dry weight) to
represent a rich media (all exchange reactions allowed to carry
flux). We have used here both this approach and additionally
implemented a minimal media containing only essential metab-
olites, carbon and nitrogen source, and oxygen. The identification of
the minimal media was achieved using a linear optimisation based
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algorithmic approach (Senior et al, 2017), where a pseudo currency
metabolite is added to all exchange reactions of the model and the
flux for the extracellular transport reaction of this pseudo me-
tabolite is systematically altered to identify a minimal set of ex-
change reactions that can still result in model optimisation. To
implement the minimal media, the identified extracellular trans-
port reactions’ minimum flux values were set to −1,000 or to −10
mmol gDW−1 h−1, with all other extracellular transport reactions’
minimum flux set to zero. The identified media composition is
provided as Table S7 and a computational implementation of the
described minimal media identification approach is provided in
Python (see the Data Availability section).
Data Availability
All relevant data are presented in the main and supplementary
texts. The SBML model of the SARS-CoV-2–infected lung cell is also
available at BioModels (Malik-Sheriff et al, 2020) under id;
MODEL2010280002 (https://www.ebi.ac.uk/biomodels/MODEL2010280002).
All sourcecodeused in thisworkareavailableonour researchgroupGitHub
web pages at: https://github.com/OSS-Lab/FBAhv.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000869.
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Robinson JL, Kocabaş P, Wang H, Cholley PE, Cook D, Nilsson A, Anton M,
Ferreira R, Domenzain I, Billa V (2020) An atlas of human metabolism.
Sci Signal 13: eaaz1482. doi:10.1126/scisignal.aaz1482
Segrè D, Vitkup D, Church GM (2002) Analysis of optimality in natural and
perturbedmetabolic networks. Proc Natl Acad Sci U S A 99: 15112–15117.
doi:10.1073/pnas.232349399
Senior NJ, Sasidharan K, Saint RJ, Scott AE, Tyson MS, Ireland PM, Bullifent HL,
Yang ZR, Moore K, Oyston PCF, et al (2017) An integrated
computational-experimental approach reveals Yersinia pestis genes
essential across a narrow or a broad range of environmental
conditions. BMC Microbiol 17: 163. doi:10.1186/s12866-017-1073-8
Schuster S, Pfeiffer T, Fell DA (2008) Is maximization of molar yield in
metabolic networks favoured by evolution? J Theor Biol 252: 497–504.
doi:10.1016/j.jtbi.2007.12.008
Simmonds P, Aiewsakun P, Katzourakis A (2019) Prisoners of war: Host
adaptation and its constraints on virus evolution. Nat Rev Microbiol
17: 321–328. doi:10.1038/s41579-018-0120-2
Swainston N, Smallbone K, Hefzi H, Dobson PD, Brewer J, Hanscho M, Zielinski
DC, Ang KS, Gardiner NJ, Gutierrez JM, et al (2016) Recon 2.2: From
reconstruction to model of human metabolism.Metabolomics 12: 109.
doi:10.1007/s11306-016-1051-4
Thiele I, Swainston N, Fleming RMT, Hoppe A, Sahoo S, Aurich MK,
Haraldsdottir H, Mo ML, Rolfsson O, Stobbe MD, et al (2013) A
community-driven global reconstruction of human metabolism. Nat
Biotechnol 31: 419–425. doi:10.1038/nbt.2488
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A,
Pontén F (2015) Tissue-based map of the human proteome. Science
347. doi:10.1126/science.1260419
Waldbauer JR, Coleman ML, Rizzo AI, Campbell KL, Lotus J, Zhang L (2019)
Nitrogen sourcing during viral infection of marine cyanobacteria. Proc
Natl Acad Sci U S A 116: 15590–15595. doi:10.1073/pnas.1901856116
Wang Q-Y, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, Zhou J, Poh MK, de
Sessions PF, Niyomrattanakit P, et al (2011) Inhibition of dengue virus
through suppression of host pyrimidine biosynthesis. J Virol 85:
6548–6556. doi:10.1128/jvi.02510-10
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li
C, Sayeeda Z, et al (2018) DrugBank 5.0: A major update to the
DrugBank database for 2018. Nucleic Acids Res 46: D1074–D1082.
doi:10.1093/nar/gkx1037
Wong EHM, Smith DK, Rabadan R, Peiris M, Poon LLM (2010) Codon usage bias
and the evolution of influenza A viruses. Codon usage biases of
influenza virus. BMC Evol Biol 10: 253. doi:10.1186/1471-2148-10-253
Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Jarreta JA, Amode MR, Armean
IM, Azov AG, Bennett R, et al (2020) Ensembl 2020. Nucleic Acids Res 48:
D682–D688. doi:10.1093/nar/gkz966
Yin J, Redovich J (2018) Kinetic modeling of virus growth in cells.Microbiol Mol
Biol Rev 82: e00066-17. doi:10.1128/mmbr.00066-17
You L, Suthers PF, Yin J (2002) Effects of Escherichia coli physiology on growth
of phage T7 in vivo and in silico. J Bacteriol 184: 1888–1894. doi:10.1128/
JB.184.7.1888-1894.2002
Yu Y, Clippinger AJ, Alwine JC (2011) Viral effects on metabolism: Changes in
glucose and glutamine utilization during human cytomegalovirus
infection. Trends Microbiol 19: 360–367. doi:10.1016/j.tim.2011.04.002
License: This article is available under a Creative
Commons License (Attribution 4.0 International, as
described at https://creativecommons.org/
licenses/by/4.0/).
Metabolic inhibition of SARS-CoV-2 Delattre et al. https://doi.org/10.26508/lsa.202000869 vol 4 | no 1 | e202000869 12 of 12
